Autonomix Medical Inc Stock Price, News & Analysis

Autonomix Medical (NASDAQ: AMIX) announced the approval of a protocol amendment by the Ethics Committee for its ongoing proof-of-concept human clinical trial. The trial evaluates the safety and efficacy of delivering transvascular energy to ablate nerves and mitigate pain in pancreatic cancer patients. Following the treatment of the first five 'lead-in' patients, the protocol was amended to gather additional data on tumor encroachment and other bio-measurements, and to refine inclusion criteria based on patient-reported pain levels. Autonomix plans to release topline results from the lead-in patients soon and aims to complete trial enrollment by year-end. The company's catheter-based technology seeks to offer a targeted, effective alternative to current pain management methods.

Autonomix Medical (NASDAQ: AMIX) reported its FY2024 financials and corporate updates. Highlights include a net loss of $15.4M, up from $2.0M in FY2023, and an IPO raising $11.2M gross. The company has $8.6M cash on hand, sufficient to fund operations until Q1 2025. Key achievements involve the initiation of PoC human trials for RF ablation in pancreatic cancer pain, partnerships, and significant patent issuances. Clinical milestones set for 2024 include topline results from the first five PoC study patients in June and device design completion for clinical use. G&A and R&D expenses rose significantly due to IPO-related costs and clinical advancements.

Autonomix Medical announced the successful completion of a preclinical animal study demonstrating that targeted nerve ablation can significantly reduce tumor mass growth and metastases in pancreatic cancer. The study, involving mice injected with human pancreatic tumor cells, showed a 60% reduction in local invasion and a 40% decrease in liver metastases in the experimental group treated with peri-pancreatic neural ablation compared to the control group. CEO Lori Bisson highlighted these findings as supportive of the theory that nerve fibers contribute to cancer metastasis and emphasized potential future clinical applications. The company's technology aims to provide a more precise and effective alternative to current treatments for pancreatic cancer-related pain.

Autonomix Medical (NASDAQ: AMIX), a company specializing in medical devices for nervous system diseases, will participate in the Virtual Investor Closing Bell Series on May 16, 2024, at 4:00 PM ET. CEO Lori Bisson will present a corporate overview and business outlook. The event will be live-streamed on the company's website, with an opportunity for live questions from investors. A replay will be available for 90 days post-event.